Journal
HEART VIEWS
Volume 22, Issue 4, Pages 275-279Publisher
WOLTERS KLUWER MEDKNOW PUBLICATIONS
DOI: 10.4103/HEARTVIEWS.HEARTVIEWS_39_21
Keywords
Heart failure; myosin; omecamtiv mecarbil
Categories
Ask authors/readers for more resources
This article highlights a newer class of medications targeting reduced myocardial contractility in congestive heart failure (HF), despite ongoing morbidity and mortality associated with the condition. Trials have shown promising effects on HF outcomes, emphasizing the potential for improved therapeutic options.
Congestive heart failure (HF) remains a major cause of cardiac-related morbidity and mortality, despite major therapeutic advancements. A newer class of medications has recently been developed which targets the root cause of HF, which is reduced myocardial contractility. This article aims to highlight the cardiac myosin activator class of drugs and the trials to date highlighting their effects on HF outcomes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available